RECRUITING

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

Talk to us

Conditions

Advanced Solid TumorMetastatic Solid TumorJZP898

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.

Official Title

A Phase 1, First-in-human, Open-label, Multicenter Study of JZP898 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Quick Facts

Study Start:2023-11-07
Study Completion:2028-05-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06108050

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Clinical Trial Disclosure & Transparency
CONTACT
215-832-3750
ClinicalTrialDisclosure@JazzPharma.com

Study Locations (Sites)

California Cancer Associates for Research and Excellence
Encinitas, California, 92024
United States
California Cancer Associates for Research and Excellence
Fresno, California, 93270
United States
Duke University Medical Center - Duke Cancer Institute
Durham, North Carolina, 27710
United States
Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
United States
SCRI Oncology Partners
Nashville, Tennessee, 37203
United States
Texas Oncology - Baylor Charles A Sammons Cancer Center
Dallas, Texas, 75246
United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
United States
Virginia Cancer Specialists
Fairfax, Virginia, 22031
United States

Collaborators and Investigators

Sponsor: Jazz Pharmaceuticals

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-07
Study Completion Date2028-05-31

Study Record Updates

Study Start Date2023-11-07
Study Completion Date2028-05-31

Terms related to this study

Keywords Provided by Researchers

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • JZP898

Additional Relevant MeSH Terms

  • Advanced Solid Tumor
  • Metastatic Solid Tumor